Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Boyer

Showing results (491-500 of 513) with videos related to

Pageof 52
Sort By:
Molecular Cancer Therapeutics|September 28, 2016
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1Lawrence J Thomas, Laura Vitale, Thomas O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyE Van Cutsem, C Twelves, J Cassidy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancerD E Gerber, L Horn, M Boyer, et al.
Radiology|May 1, 1996
Resolution of intracranial calcifications in infants with treated congenital toxoplasmosisD V Patel, E M Holfels, N P Vogel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, E-H Tan, K O'Byrne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2015
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected InfantsDespina Contopoulos-Ioannidis, Kelsey M Wheeler, Raymund Ramirez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialA Davidson, A-S Veillard, A Tognela, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
Pageof 52

Showing results (491-500 of 513) with videos related to

Sort By:
Pageof 52
Molecular Cancer Therapeutics|September 28, 2016
Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1Lawrence J Thomas, Laura Vitale, Thomas O'Neill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III studyE Van Cutsem, C Twelves, J Cassidy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancerD E Gerber, L Horn, M Boyer, et al.
Radiology|May 1, 1996
Resolution of intracranial calcifications in infants with treated congenital toxoplasmosisD V Patel, E M Holfels, N P Vogel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 21, 2017
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialL Paz-Ares, E-H Tan, K O'Byrne, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2015
Clustering of Toxoplasma gondii Infections Within Families of Congenitally Infected InfantsDespina Contopoulos-Ioannidis, Kelsey M Wheeler, Raymund Ramirez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialA Davidson, A-S Veillard, A Tognela, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Cancer Chemotherapy and Pharmacology|June 20, 2006
Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG)W Yeo, M Boyer, H C Chung, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)S Peters, U Dafni, M Boyer, et al.
Pageof 52